Actively Recruiting
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Led by University Health Network, Toronto · Updated on 2025-12-03
144
Participants Needed
1
Research Sites
149 weeks
Total Duration
On this page
Sponsors
U
University Health Network, Toronto
Lead Sponsor
M
Myeloma Canada
Collaborating Sponsor
AI-Summary
What this Trial Is About
Patients with multiple myeloma experience a wide range of physical and psychological symptoms from the time of their diagnosis. Meanwhile, patients with aggressive lymphomas undergo unpredictable illness courses, resulting in goals of care conversations occurring late in the illness trajectory and aggressive care being received in the last 30 days of life. Early palliative care alongside usual cancer care has been shown to improve patient outcomes such as symptom burden, mood, and quality of life in patients with solid tumours (e.g. lung, breast or gynecological cancers), but has not been explored among patients with blood cancers to date. The goal of this clinical trial is to a brief early palliative care intervention for patients with multiple myeloma and aggressive B cell lymphoma and their caregivers (lymphoma only) attending the Princess Margaret Cancer Centre. The main goals of the study are: * To see if it is possible to apply the early palliative care intervention for patients with multiple myeloma and aggressive lymphoma and their caregivers (lymphoma only) * To see if this early palliative care intervention works well for these patients and caregivers * To compare patient and caregiver experiences with early palliative care and usual care * To explore perceptions and experiences of providing palliative care among healthcare providers involved in the care of these patients and caregivers. Patients, and their respective caregivers if participating, will be randomly assigned to one of two groups: one group will receive early palliative care in addition to usual care from their blood cancer doctor, and the other group will receive usual care from their blood cancer doctor only. All participants will be asked to fill out questionnaires about their quality of life, symptom burden, mood, and satisfaction with care throughout the study. Researchers will compare the results between the two groups to see if there are any improvements in quality of life for the patients who received early palliative care and their caregivers. Some patients and caregivers will be asked to take part in interviews at the end of the trial to answer questions about their experience taking part in the study. Some healthcare providers who care for these patients will also be asked to take part in interviews at the end of the trial to describe their perceptions and experiences of providing palliative care. The researchers will use the results of this study to guide in the development of a larger clinical trial.
CONDITIONS
Official Title
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- New diagnosis of multiple myeloma or disease progression requiring treatment change, or relapsed/refractory aggressive B cell lymphoma after one prior therapy
- Eastern Cooperative Oncology Group (ECOG) performance status between 0 and 3
- Willing to complete symptom screening
- At least one symptom score of 3 or higher on the ESAS-r-plus scale at recruitment
- Caregivers aged 18 years or older caring for patients with relapsed B cell lymphoma
- Caregivers willing to attend at least one palliative care clinic visit with the patient
- Healthcare providers who are specialized physicians, fellows, clinical nurse specialists, or clinic nurses working with multiple myeloma patients for at least 12 months
You will not qualify if you...
- Insufficient English literacy to complete study procedures
- Hematologist-determined poor cognitive status
- Current involvement with a palliative care team at Princess Margaret or elsewhere
- Not receiving ongoing follow-up with the malignant hematology team at Princess Margaret
- Caregivers without sufficient verbal or written English skills
- Caregivers of patients not participating in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Actively Recruiting
Research Team
B
Breffni Hannon, MB BCh BAO, MMedSci, MCFP
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here